Fatkin Diane, Santiago Celine F, Huttner Inken G, Lubitz Steven A, Ellinor Patrick T
Molecular Cardiology Division, Victor Chang Cardiac Research Institute, Sydney, NSW 2010, Australia; St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Australia; Cardiology Department, St. Vincent's Hospital, Sydney, NSW 2010, Australia.
Molecular Cardiology Division, Victor Chang Cardiac Research Institute, Sydney, NSW 2010, Australia.
Heart Lung Circ. 2017 Sep;26(9):894-901. doi: 10.1016/j.hlc.2017.04.008. Epub 2017 May 11.
Genetic variation is an important determinant of atrial fibrillation (AF) susceptibility. Numerous rare variants in protein-coding sequences of genes have been associated with AF in families and in early-onset cases, and chromosomal loci harbouring common risk variants have been mapped in AF cohorts. Many of these loci are in non-coding regions of the human genome and are thought to contain regulatory sequences that modulate gene expression. Disease genes implicated to date have predominantly encoded cardiac ion channels, with predicted mutation effects on the atrial action potential duration. More recent studies have expanded the spectrum of disease-associated genes to include myocardial structural components and have highlighted an unsuspected role for cardiac transcription factors. These paradigm-shifting discoveries suggest that abnormalities of atrial specification arising during cardiac development might provide a template for AF in later adult life. With the escalating pace of variant discovery, there is an increasing need for mechanistic studies not only to evaluate single variants, but also to determine the collective effects of each person's burden of rare and common genetic variants, co-morbidities and lifestyle factors on the atrial substrate for arrhythmogenesis. Elucidation of an individual's genetic predisposition and modifiable environmental risk factors will facilitate personalised approaches to AF treatment.
基因变异是心房颤动(AF)易感性的重要决定因素。基因蛋白质编码序列中的众多罕见变异已在家族性和早发性病例中与AF相关联,并且在AF队列中已定位了含有常见风险变异的染色体位点。其中许多位点位于人类基因组的非编码区域,被认为包含调节基因表达的调控序列。迄今为止涉及的疾病基因主要编码心脏离子通道,预测其突变会影响心房动作电位持续时间。最近的研究已将疾病相关基因的范围扩大到包括心肌结构成分,并突出了心脏转录因子意想不到的作用。这些范式转变的发现表明,心脏发育过程中出现的心房特化异常可能为成年后期的AF提供了一个模板。随着变异发现速度的不断加快,越来越需要进行机制研究,不仅要评估单个变异,还要确定每个人的罕见和常见基因变异负担、合并症和生活方式因素对心律失常发生的心房基质的综合影响。阐明个体的遗传易感性和可改变的环境风险因素将有助于AF治疗的个性化方法。